Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$33.00K$33.00Kderivedno prior Q4 2013 on file Net Income-$18.64M-$18.64MderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$2,000N/M Operating Incomederived-$1,642,000N/M Operating Cash Flowderived-$1,038,000N/M Margins · derivedGross margin-6.1%
Operating margin-4975.8%
Net margin-56472.7%
ended Dec 31, 2014 · filed Mar 31, 2015 · 90 d after period end